A Case of Small Cell Lung Carcinoma Harboring an EML4–ALK Fusion with Partial Response to Crizotinib

•A patient with metastatic small cell lung cancer (SCLC) had an echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) fusion. •He had a partial response to crizotinib in the primary lesions. •ALK tyrosine kinase inhibitors should be considered in SCLC patients with EML4–ALK fusions. •Gene testing should be performed in young SCLC patients with a limited smoking history. •A patient with metastatic small cell lung cancer (SCLC) had an echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) fusion. •He had a partial response to crizotinib in the primary lesions. •ALK tyrosine kinase inhibitors should be considered in SCLC patients with EML4–ALK fusions. •Gene testing should be performed in young SCLC patients with a limited smoking history.